REG - Dr. Martens PLC - CFO Appointment

Dr MartensAnnouncement

14/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231114:nRSN2912Ta&default-theme=true

RNS Number : 2912T  Dr. Martens PLC  14 November 2023

 

14 November 2023

Dr. Martens plc

 

CFO appointment

 

Dr. Martens plc ('the Company') announces that Giles Wilson has been appointed
to the role of Chief Financial Officer (CFO). Giles will join Dr. Martens and
take up his role in 2024, with the date to be confirmed and announced in due
course.

Giles is an experienced CFO who joins Dr. Martens from William Grant &
Sons Limited, one of the largest global spirits companies, owners of premium
brands including Glenfiddich Scotch Whisky, The Balvenie Whisky and Hendrick's
Gin. Prior to this, Giles was at John Menzies plc as CFO (2016-20), and then
subsequently became CEO (2019-20). Giles qualified as a chartered accountant
with PwC and previously held a senior role at Commercial Estates Group.

Paul Mason, Chair, said "Following a rigorous selection process, we are
delighted to appoint Giles as CFO. He is a very capable finance leader with
extensive experience in a number of sectors and, most recently, his time in
the branded spirits industry has given him a good grounding in global brands
and wholesale distribution management. His knowledge of the public markets
will be a valuable asset to the team as Dr. Martens continues its growth in
the listed environment. I look forward to him joining the Board."

Kenny Wilson, CEO, said "I am thrilled that Giles will be joining the
leadership team and the Board. He brings a range of complementary skills and
past experience that is highly relevant to our brand-first strategy. I am
looking forward to working with him on the next phase of Dr. Martens' journey
to become a £2billion revenue footwear brand."

Giles Wilson said "Dr. Martens is an iconic brand I have long admired, and I
have been impressed by the passion and ambition within the business. I am
excited to be joining at such an important stage in the Company's growth and I
am looking forward to working with Kenny and the team to drive the strategy
forward."

Jon Mortimore, who is retiring from the Company as previously announced, has
agreed to stay with the business until the end of the financial year.

There are no further disclosures required in respect of this appointment
pursuant to Listing Rule 9.6.13.

 

Enquiries

Investors and analysts

Bethany Barnes, Director of Investor Relations
Bethany.Barnes@drmartens.com    +44 7825 187465

Beth Callum, Senior Investor Relations Analyst
Beth.Callum@drmartens.com  +44 203 995 2644

 

Press
 

H/Advisors Maitland
                                +44 207 379 5151

   Clinton Manning
                                +44 7711 972662

 

Gill Hammond, Director of Communications
                                +44 7384 214248

 

 

Notes

Remuneration Arrangements

Giles Wilson's remuneration arrangements have been set in accordance with the
Directors' Remuneration Policy detailed in the FY23 Annual Report.  Further
details will be set out in the Directors' Remuneration Report for FY24.

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire.
Produced originally for workers looking for tough, durable boots, the brand
was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens has since transcended its working-class roots while
still celebrating its proud heritage and, six decades later, "Docs" or "DM's"
are worn by people around the world who use them as a symbol of empowerment
and their own individual attitude. The Company is a constituent of the FTSE
250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABJBRTMTBBBJJ